Freezor cardiac cryoablation catheters approved to treat paediatric AVNRT

5617

Medtronic has announced that the Freezor and Freezor Xtra cardiac cryoablation catheters are approved by the US Food and Drug Administration (FDA) to treat the growing prevalence of paediatric atrioventricular nodal reentrant tachycardia (AVNRT).

AVNRT is the most common form of supraventricular tachycardia (SVT), and is a life-threatening abnormal heart rhythm, with 89,000 cases each year and growing. Nearly 35% of AVNRT cases occur in paediatrics, or, children under the age of 18. Due to an abnormal circuit within the heart’s conduction system, AVNRT causes a very rapid heart rhythm, and if left untreated, can affect the heart’s ability to pump normally, leading to palpitations, lightheadedness, and syncope.

Catheter ablation is a first-line therapy for treatment of AVNRT. The Freezor and Freezor Xtra catheters are flexible, single-use devices used to freeze cardiac tissue and block unnecessary electrical signals within the heart. The Freezor family enables safe and effective focal cryoablation therapy and has treated more than 140,000 patients across 67 countries. Cryoablation can reduce the risk of permanent AV block, a complication of AVNRT procedures performed with radiofrequency (RF) ablations that results in the partial or complete interruption of the heart’s electrical signals, which dangerously disrupts heart rhythm.

“There are very few devices approved to treat medically complex paediatric cardiology patients today,” said Bryan C Cannon, professor of paediatrics (Mayo Clinic, Rochester, USA) and past president of the Pediatric & Congenital Electrophysiology Society (PACES). “With an FDA indication expansion, the Freezor and Freezor Xtra cardiac cryoablation catheters allow even the youngest of cardiology patients access to a safe, life-enhancing technology that will help advance cardiac care for AVNRT.”

The indication expansion approval is supported by results from ICY-AVNRT and multiple paediatric randomised, multicentre studies that demonstrated the safety and effectiveness of the treatment of AVNRT using the Freezor and Freezor Xtra cardiac cryoablation catheters. ICY-AVNRT data reported acute procedural success of 95% with no reports of permanent pacemaker due to complete AV block. The larger body of evidence, including a total of sixteen studies, also observed high efficacy rates and low adverse events.

The Freezor cardiac cryoablation catheter was first commercially available in the USA for adult use of AVNRT in 2003, followed by the Freezor Xtra cardiac cryoablation catheter in 2016. The Freezor family of cryoablation catheters also includes the Freezor MAX cardiac cryoablation catheter, which is approved for use in conjunction with the Arctic Front Advance cryoballoon for the treatment of atrial fibrillation (AF).

“We are proud of our work with PACES and FDA in this first-of-its-kind, multi-stakeholder initiative to address a critical patient population,” said Rebecca Seidel, president of the Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. “The shared commitment to collaborate and grow this therapy’s unique position to treat AVNRT patients demonstrates our confidence in the proven safety and efficacy of our cryoablation technology.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here